Pathos AI said on October 23 that it has raised $237 million in a Series E financing led by Bristol Myers Squibb, valuing the New York company at about $3 billion, with participation from existing investors, Reuters reported. The financing is paired with a three-way collaboration among Pathos, Bristol Myers and Tempus AI to develop artificial intelligence tools for Alzheimer disease and other neurological disorders, using Pathos’s platform, called Pathos Foundry.
The data leg is priced separately. Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to track outcomes and study disease biology, and Pathos will license that data under a five-year agreement worth $55 million. Pathos will apply Foundry to the dataset at scale to generate and test hypotheses on disease biology and to inform more targeted, adaptive trial designs. Bristol Myers gains non-exclusive strategic access to Foundry across its broader portfolio and three-year exclusive rights to use the platform for its neuroscience development programs.
Proceeds will scale Foundry and advance Pathos’s own AI-driven pipeline, including the experimental cancer drug JSKN016 and an AstraZeneca-partnered experimental breast cancer drug, Reuters reported. That pipeline is what separates Pathos from a pure software vendor: the company both sells a discovery platform and owns drug candidates the platform produced, so the Bristol Myers exclusivity in neuroscience sits alongside, rather than replacing, its oncology work.
Two cautions belong with the headline numbers. The $3 billion valuation and the $237 million round both originate in the companies’ own announcement; Endpoints News and STAT reported the same event from that announcement, and Reuters’ independent report is what corroborates the figures here. Second, nothing in the announcement is clinical evidence: no drug in the collaboration has human efficacy data attached to it, and the deliverable Bristol Myers has actually bought is access, exclusivity and a dataset, not a medicine.